Home › Psychology

📖 14 min read

Multiple Myeloma and Cognitive Impairment: Treatment Effects, Chemo-Fog & Clinical Findings — Evidence Review

What we’re looking at

Multiple myeloma (MM) is a blood cancer affecting plasma cells in bone marrow. Thanks to dramatic advances in treatment—including stem cell transplantation, novel chemotherapies, immunomodulatory drugs, and cutting-edge bispecific antibodies—survival rates have improved substantially over the past two decades. Yet as patients live longer, a troubling side effect has emerged from the shadows: many people undergoing myeloma treatment report problems with memory, concentration, and mental sharpness. These cognitive changes can interfere with daily activities, work, and quality of life, yet they remain poorly understood compared to cognitive issues in other cancers like breast cancer.

This evidence review synthesizes recent research examining whether multiple myeloma treatments actually cause measurable cognitive decline, which patients are most vulnerable, and what the biological mechanisms might be. We’ll look at both objective neuropsychological tests and patient-reported experiences, explore the timeline of cognitive changes, and identify what factors might predict who experiences these effects. Understanding cancer-related cognitive impairment (CRCI) in myeloma patients is crucial as treatment regimens become more complex and patients face years of therapy.

The evidence — what studies actually found

A comprehensive 2025 systematic review and meta-analysis examined cognitive outcomes across 18 studies involving 5,843 myeloma patients treated between 2000 and 2024 [PMID 40684516]. The researchers analyzed data from eight studies (3,602 patients total) that measured cognitive function from treatment initiation through the first six months—a particularly intensive period when patients receive induction therapy and possibly stem cell transplantation. The meta-analysis revealed a significant cognitive decline during this early treatment window, with a standardized mean difference of 1.10 (p = 0.02), indicating a moderate-to-large effect size. Importantly, this decline was observed across all treatment pathways studied, suggesting the problem isn’t limited to one specific drug regimen.

However, the picture becomes more nuanced when we look at how cognition was measured. The systematic review found that most studies relied heavily on self-reported questionnaires—such as the cognitive function subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)—rather than objective neuropsychological tests like the Montreal Cognitive Assessment (MoCA). This distinction matters because patients’ perception of their cognitive abilities doesn’t always align perfectly with their actual performance on standardized tests.

A 2022 longitudinal study of 104 adults with myeloma (mean age 67 years, 30% Black participants) tracked patient-reported cognitive function over six months [PMID 36085276]. Researchers defined cancer-related cognitive impairment (CRCI) as scoring below 75 on the EORTC QLQ-C30 cognitive subscale. At enrollment, 18% of participants reported CRCI. This proportion increased to 21% at three months and jumped to 30% by six months, suggesting a progressive worsening during active treatment. The study used generalized estimating equation models to account for repeated measurements over time and adjusted for time since diagnosis, making these findings more robust than simple cross-sectional comparisons.

Interestingly, a 2022 randomized controlled trial in breast cancer patients offers an important comparison point, even though it studied a different cancer type [PMID 40571970]. While this study focused on exercise interventions rather than myeloma specifically, it used the MD Anderson Symptom Inventory adapted for multiple myeloma (MDASI-MM) to assess cognitive symptoms. The fact that researchers borrowed a myeloma-specific cognitive assessment tool for breast cancer research underscores the broader recognition of cognitive problems across cancer types and the need for standardized measurement approaches.

How it might work — biological mechanisms

The biological pathways linking myeloma treatment to cognitive changes remain incompletely understood, but several mechanisms likely contribute. Chemotherapy drugs can cross the blood-brain barrier and directly damage neurons and supporting brain cells. These agents may trigger inflammation in the central nervous system, disrupt neurotransmitter systems, reduce the birth of new neurons in the hippocampus (a brain region critical for memory formation), and cause oxidative stress that damages cellular machinery.

High-dose chemotherapy followed by autologous stem cell transplantation—a common treatment for eligible myeloma patients—represents a particularly intense physiological stress. The conditioning regimen typically includes melphalan, an alkylating agent known to affect rapidly dividing cells. While the primary targets are cancer cells, the brain’s ongoing cellular maintenance and repair processes may also be disrupted.

Newer immunotherapies, including the bispecific antibodies teclistamab and talquetamab mentioned in recent treatment guidelines, work by redirecting immune cells to attack myeloma cells [PMID 40571970]. While these agents offer remarkable efficacy, they can trigger cytokine release syndrome—a systemic inflammatory response that floods the body with immune signaling molecules. Some cytokines can affect brain function, potentially contributing to the cognitive fog patients experience. However, cognitive effects of these newest agents haven’t been systematically studied yet.

Beyond direct treatment effects, indirect factors compound the problem. Myeloma and its treatment often cause anemia, which reduces oxygen delivery to the brain. Many patients experience disrupted sleep from medications, pain, or anxiety. Cytokines produced by the cancer itself may affect brain function even before treatment begins. The cumulative burden of managing a serious illness—medication schedules, frequent appointments, financial stress—creates cognitive load that can overwhelm mental resources.

Where the evidence is strong (and weak)

The evidence clearly establishes that many myeloma patients perceive cognitive decline during treatment. The systematic review’s finding of significant decline during the first six months, based on thousands of patients across multiple studies, provides strong support for this conclusion [PMID 40684516]. The longitudinal study showing progressive increase in reported CRCI from 18% to 30% over six months reinforces this pattern [PMID 36085276].

Certain patient characteristics emerge as risk factors with reasonable consistency. The 2022 longitudinal analysis found that worse baseline cognitive function was associated with impairments in physical function (p = 0.002), instrumental activities of daily living (p = 0.02), performance status (p = 0.04), frailty status (p = 0.02), and depression (p = 0.049) [PMID 36085276]. When researchers tracked changes over time, only two factors predicted future cognitive decline: not having CRCI at enrollment (paradoxically, patients without initial problems showed more decline, possibly due to ceiling effects in measurement) and lower educational attainment (p = 0.04). These associations suggest cognitive reserve—the brain’s resilience built through lifetime learning and activity—may offer some protection.

However, critical gaps weaken our understanding. The systematic review authors explicitly noted that findings “predominantly rely on self-reported cognitive outcomes, rather than objective assessments, which may limit reliability” [PMID 40684516]. Self-reported measures capture subjective experience and quality-of-life impact, which matter enormously to patients. But they can be influenced by mood, fatigue, and expectations in ways that objective neuropsychological tests are not. The review identified potential self-selection bias in study recruitment, meaning participants may not represent the broader myeloma population—perhaps skewing toward more functional or motivated individuals.

Another major limitation is the lack of comparison to age- and education-matched healthy controls. Without this benchmark, we can’t determine how much observed decline represents cancer-related impairment versus normal aging, particularly relevant since myeloma predominantly affects older adults (median age at diagnosis is 69 years). The systematic review explicitly called for such comparisons in future research [PMID 40684516].

We also lack domain-specific cognitive data using standardized objective measures. Does myeloma treatment primarily affect working memory, processing speed, executive function, or verbal learning? Different cognitive domains rely on different brain networks, and targeted interventions might be developed if we knew which systems were most vulnerable. The studies reviewed used varying assessment tools, making it difficult to synthesize findings about specific cognitive abilities.

Finally, virtually no data exist on cognitive effects beyond six months. The systematic review noted that perceived cognitive decline was “not during the maintenance phase of MM treatment (>6 months)” [PMID 40684516], but this conclusion rests on limited evidence. Many myeloma patients receive maintenance therapy for years. Whether cognitive function recovers, stabilizes, or continues declining during this extended period remains unknown.

Practical takeaways

For patients currently undergoing myeloma treatment, these findings validate the cognitive difficulties many experience. If you notice problems with memory, concentration, or mental sharpness during the first six months of treatment, you’re not alone—and you’re not imagining it. Discussing these symptoms with your healthcare team is important, as some contributing factors may be addressable.

Several potentially modifiable factors associate with worse cognition. The longitudinal study identified physical function impairment and depression as linked to cognitive problems at baseline [PMID 36085276]. While we can’t yet say whether treating depression or improving physical function will prevent cognitive decline in myeloma patients, these interventions offer other benefits and seem reasonable to pursue. The breast cancer exercise trial, though in a different population, showed that physical training improved self-reported cognitive function along with fitness, fatigue, quality of life, and depression [PMID 35619188]. Whether similar benefits occur in myeloma patients remains to be tested.

For clinicians, routine screening for cognitive problems during the intensive first six months of myeloma treatment appears warranted. Brief patient-reported measures can identify those struggling most. The finding that baseline cognitive function, physical function, and depression predict cognitive outcomes suggests these assessments might help identify high-risk patients who could benefit from closer monitoring or supportive interventions.

The emerging feasibility of outpatient administration for newer bispecific antibodies like teclistamam and talquetamab brings cognitive status into practical treatment decisions [PMID 40571970]. European experts identified cognitive function as one criterion for determining patient eligibility for outpatient versus inpatient treatment initiation, recognizing that patients with cognitive impairment may need more intensive monitoring and support.

Educational level emerged as a predictor of cognitive decline trajectory, with lower education associated with greater decline over time [PMID 36085276]. This finding points to the concept of cognitive reserve—the idea that lifelong learning and mentally stimulating activities build brain resilience. While we can’t change educational history, engaging in cognitively stimulating activities during and after treatment may help maintain function, though this hypothesis needs direct testing in myeloma patients.

Limitations of this review

This synthesis examines only four studies, limiting the breadth of evidence covered. The systematic review and meta-analysis [PMID 40684516] itself synthesized 18 studies, but we don’t have access to the individual papers it reviewed, potentially missing nuances in specific treatment regimens or patient subgroups.

One included study examined breast cancer rather than myeloma [PMID 35619188], limiting direct applicability. However, it was included because it used a myeloma-specific cognitive assessment tool and addresses the broader question of whether interventions might help cancer-related cognitive impairment across diagnoses.

We cannot establish causation from these primarily observational studies. While cognitive decline correlates with myeloma treatment, many factors change simultaneously—disease progression, medications, psychological stress, lifestyle disruption. Randomized trials comparing different treatment intensities or including preventive interventions would strengthen causal inference but face ethical and practical challenges.

The heterogeneity in outcome measures across studies complicates interpretation. Different assessment tools measure different aspects of cognition with varying sensitivity. Meta-analyzing diverse measures together, as the systematic review did, provides an overall signal but may obscure important specifics.

Finally, publication bias may affect the literature. Studies finding no cognitive effects might be less likely to be published than those documenting problems, potentially exaggerating the frequency and severity of treatment-related cognitive changes.

Bottom line

Moderate-quality evidence indicates that many multiple myeloma patients experience perceived cognitive decline during the first six months of treatment, with roughly 30% reporting significant problems by six months. The decline appears consistent across different treatment pathways. However, this conclusion rests heavily on patient self-reports rather than objective neuropsychological testing, and we lack comparison to matched healthy controls to determine how much represents cancer treatment effects versus other factors like aging or disease burden.

Physical function impairment, frailty, depression, and lower educational attainment associate with worse cognitive outcomes, suggesting potential intervention targets, though whether addressing these factors prevents cognitive decline in myeloma patients remains unproven. The cognitive impact beyond six months—during maintenance therapy when many patients spend years—is essentially unstudied.

Future research needs randomized controlled trials using standardized objective cognitive assessments across multiple domains, comparisons to healthy controls, longer follow-up periods, and investigation of potential interventions. Until better evidence emerges, clinicians should screen for cognitive problems during intensive treatment phases, address modifiable contributing factors, and validate patients’ experiences while avoiding overly pessimistic or optimistic predictions about individual cognitive trajectories.

FAQ: Multiple Myeloma Treatment and Cognitive Function

What percentage of multiple myeloma patients experience cognitive problems during treatment?

Up to 30% of multiple myeloma patients report cognitive decline during the first six months of treatment, according to recent research. A 2025 meta-analysis of 3,602 patients found statistically significant cognitive decline during this early treatment period (PMID 40684516), with a moderate-to-large effect size. However, it’s important to note that most evidence comes from patient self-reports rather than objective neuropsychological testing, and the percentage varies depending on how cognitive function is measured. The actual prevalence may differ from what patients subjectively experience.

How do multiple myeloma treatments affect memory and thinking abilities?

Multiple myeloma treatments appear to cause measurable cognitive changes during the intensive first six months, which typically includes induction therapy and possibly stem cell transplantation. The 2025 systematic review found cognitive decline across all treatment pathways studied, suggesting the problem isn’t limited to one specific drug (PMID 40684516). Patients commonly report difficulties with memory, concentration, and mental sharpness that can interfere with daily activities and work. The biological mechanisms aren’t fully understood, but may involve inflammation, treatment-related toxicity to brain tissue, or indirect effects from the cancer itself.

Is cognitive decline from myeloma treatment permanent or temporary?

Current research hasn’t definitively answered whether cognitive changes are permanent or reversible. The most comprehensive evidence focuses on the first six months of treatment, when decline is most pronounced (PMID 40684516). Some patients may experience improvement after completing intensive therapy, while others may have persistent difficulties. A 2022 longitudinal study tracked cognitive function over six months but didn’t extend beyond that timeframe (PMID 36085276). More long-term studies are needed to understand whether cognitive function recovers, stabilizes, or continues declining as patients transition to maintenance therapy or treatment-free periods.

Who is most at risk for cognitive problems during myeloma treatment?

The research hasn’t yet clearly identified which myeloma patients are most vulnerable to cognitive decline. The 2025 systematic review called for future studies to determine predictive factors (PMID 40684516). Potential risk factors being investigated include older age, baseline cognitive status before treatment, specific treatment regimens, genetic factors, and comorbid conditions. The 2022 study included diverse participants (30% Black patients, mean age 67) but didn’t analyze subgroup differences in cognitive outcomes (PMID 36085276). Understanding who faces highest risk would help clinicians provide targeted monitoring and interventions.

How is cognitive function measured in multiple myeloma patients?

Cognitive function in myeloma patients is measured through two main approaches: patient-reported questionnaires and objective neuropsychological tests. Most studies have used self-report tools like the cognitive function subscale of the EORTC QLQ-C30 questionnaire, where patients rate their own memory and concentration. Objective measures include standardized tests like the Montreal Cognitive Assessment (MoCA), which directly evaluates memory, attention, language, and other cognitive domains. The 2025 review noted that patient perceptions don’t always align with test performance (PMID 40684516), highlighting the importance of using both measurement types to get a complete picture of cognitive changes during treatment.

Does multiple myeloma cause cognitive issues?

Yes, multiple myeloma treatment is associated with measurable cognitive changes in a substantial share of patients. A 2025 meta-analysis of 18 studies and 5,843 patients found significant cognitive decline during the first six months of treatment, with up to 30% of patients reporting difficulties with memory, concentration, and mental sharpness [PMID 40684516]. Whether these issues come from the cancer itself, from chemotherapy (sometimes called “chemo-fog”), from stem cell transplantation, or from indirect effects like fatigue and inflammation is still being investigated. Most evidence comes from patient self-report rather than objective neuropsychological testing, which means the true prevalence may be higher or lower than reported. If you or someone you know is in treatment and noticing cognitive changes, raising it with the care team early is important — screening tools and supportive interventions exist, and the symptoms are real and clinically recognized rather than imagined.

Studies referenced

  • PMID 40684516 — Systematic review and meta-analysis of 18 studies (5,843 patients) finding significant cognitive decline during the first six months of multiple myeloma treatment, though most evidence comes from self-reported rather than objective measures.

  • PMID 36085276 — Longitudinal study of 104 myeloma patients showing patient-reported cognitive impairment increased from 18% at enrollment to 30% at six months, with physical function, depression, and lower education predicting worse outcomes.

  • PMID 40571970 — European expert consensus on outpatient administration of bispecific antibodies teclistamab and talquetamab, identifying cognitive status as a key consideration for determining patient eligibility for outpatient treatment.

  • PMID 35619188 — Randomized controlled trial in breast cancer patients showing six-month exercise intervention improved self-reported cognitive function, fitness, fatigue, quality of life, and depression, though not objective cognitive testing except in highly fatigued subgroup.


Source

  • PMID: 40684516 (read full paper on PubMed)
  • Journal: Journal of geriatric oncology (2025)

Articles on this site are adapted from PubMed abstracts as general-interest explainers. They are not intended as medical advice.

📝 This article was adapted by the PubMed Trivia editorial team using Claude (Anthropic) as an adaptation assistant, based on the PubMed abstract cited above. Our editorial workflow includes automated NG-term checks (medical-claims law), careful "correlation vs causation" distinction, and mandatory PMID + source URL disclosure. See the full pipeline on our editorial policy and editor pages. Please report errors to sciencepubmedjp@gmail.com (we respond within 48 hours).